NOVEL CANCER THERAPEUTIC
A novel cytotoxic compound designed for targeted delivery to cancer cells.

The Technology

The technology is based on the development of derivatives of a cytotoxic compound originally isolated from molluscs. These novel derivatives have been demonstrated to show selective toxicity in tumour cell lines and are therefore proposed as novel therapeutics against cancer.

The research team has modified these derivatives via clever design and the addition of a targeting strategy in which the drug will be delivered to specific cancer cells resulting in controlled release and subsequent cancer cell death.

IP position

An Australian draft provisional patent application is currently being drafted.

Market

Cancer continues to dominate the healthcare industry where there are still significant unmet needs in treatment regimes for many of the major forms of the disease. Novel cancer therapeutics are therefore in high demand and Pharma/Biotech companies are willing to risk significant investment into their development due to the potential for high return.

This technology represents a new therapeutic which specifically targets cancer cell populations and hence offers a low side-effect profile. It is anticipated that such a compound would gain large market share and fulfill significant unmet needs in the oncology sector.

Commercialisation

Funding is sought to further support preclinical development and efficacy studies.